NCNA Stock - NuCana plc
Unlock GoAI Insights for NCNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-22,809,000 | $-32,784,000 | $-43,696,000 | $-45,345,000 | $-32,923,000 |
| Net Income | $-18,997,000 | $-27,632,000 | $-32,021,000 | $-40,533,000 | $-30,682,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.27 | $-5.25 | $-6.25 | $-9.75 | $-10.12 |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 30th 2024 | William Blair | Downgrade | Market Perform | - |
Earnings History & Surprises
NCNAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Jun 1, 2026 | — | — | — | — |
Q2 2026 | Jun 1, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-2.69 | $-0.10 | +96.3% | ✓ BEAT |
Q3 2025 | Aug 20, 2025 | $-2.75 | $-0.16 | +94.2% | ✓ BEAT |
Q2 2025 | Jun 2, 2025 | $-2.58 | $-126.00 | -4778.0% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-486.00 | $-64.00 | +86.8% | ✓ BEAT |
Q4 2024 | Nov 25, 2024 | $-3.47 | $-456.00 | -13041.2% | ✗ MISS |
Q3 2024 | Aug 15, 2024 | $-710.00 | $-758.00 | -6.8% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-662.00 | $-32.00 | +95.2% | ✓ BEAT |
Q1 2024 | Mar 20, 2024 | $-650.00 | $-850.00 | -30.8% | ✗ MISS |
Q4 2023 | Nov 16, 2023 | $-650.00 | $-800.00 | -23.1% | ✗ MISS |
Q3 2023 | Aug 16, 2023 | $-800.00 | $-650.00 | +18.8% | ✓ BEAT |
Q2 2023 | May 17, 2023 | $-600.00 | $-900.00 | -50.0% | ✗ MISS |
Q2 2023 | Apr 4, 2023 | — | $-0.07 | — | — |
Q4 2022 | Nov 16, 2022 | $-650.00 | $-550.00 | +15.4% | ✓ BEAT |
Q3 2022 | Aug 17, 2022 | $-700.00 | $-450.00 | +35.7% | ✓ BEAT |
Q2 2022 | Jun 2, 2022 | $-950.00 | $-1050.00 | -10.5% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | — | $-0.14 | — | — |
Q4 2021 | Nov 18, 2021 | $-1250.00 | $-1050.00 | +16.0% | ✓ BEAT |
Latest News
Nucana Reappoints Hugh S. Griffith As CEO, Effective Dec. 15
➖ NeutralNuCana Presents Data Showing Clinical Activity And Favorable Safety For NUC-7738 At ESMO Congress
📈 PositiveNuCana Announces China's National Intellectual Property Administration Has Granted A Composition Of Matter Patent For NUC-7738, Its Novel Anti-Cancer Agent
📈 PositiveReported Saturday, NuCana Highlights Synergy Between NUC-7738 And PD-1 Inhibitors In RCC Organoids, Supporting Expansion Of NuTide:701 Clinical Study
📈 PositiveNuCana Publishes NuTide:303 Clinical And Preclinical Data On NUC-3373 In medRxiv And PLOS ONE
➖ NeutralNuCana Announces Compliance With All Nasdaq Continued Listing Criteria
📈 PositiveNuCana To Present Data On NUC-7738's Synergy With PD-1 Inhibitors At Upcoming Annual European Society for Medical Oncology Congress
📈 PositiveNuCana shares are trading higher after the company reported a year-over-year increase in Q2 EPS results.
📈 PositiveNuCana Q2 EPS $0.00 Up From $(0.15) YoY; Revenue $0
📈 PositiveFrequently Asked Questions about NCNA
What is NCNA's current stock price?
What is the analyst price target for NCNA?
What sector is NuCana plc in?
What is NCNA's market cap?
Does NCNA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NCNA for comparison